Processa Pharmaceuticals Stock

Processa Pharmaceuticals ROE

The Return on Equity (ROE) of Processa Pharmaceuticals (PCSA) as of Aug 7, 2026 is -707.46 %. In the previous year, Return on Equity (ROE) was -222.92 % — a change of 217.36% (lower).

ROE

-707.46 %

YoY

217.36%

Last updated:

In 2026, Processa Pharmaceuticals's return on equity (ROE) was -707.46 %, a 217.36% increase from the -222.92 % ROE in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Processa Pharmaceuticals Stock analysis

What does Processa Pharmaceuticals do? Processa Pharmaceuticals is one of the most popular companies on Eulerpool.

ROE Details

Decoding Processa Pharmaceuticals's Return on Equity (ROE)

Processa Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Processa Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Processa Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Processa Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Processa Pharmaceuticals stock

Return on Equity (ROE) of Processa Pharmaceuticals is -707.46 % in 2026.

Return on Equity (ROE) of Processa Pharmaceuticals changed from -222.92 % to -707.46 %, representing a 217.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Processa Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Processa Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Processa Pharmaceuticals

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Processa Pharmaceuticals